咱们结婚吧

A |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。    8月25日消息，日前，华为正式发布行业首款阔直板手机——华为Pura X View，新机将于8月28日开启预售，价格暂未公布。     随着华为率先入局，阔直板手机这一全新品类也开始受到更多厂商关注。    数码博主“数码闲聊站”透露，目前除H（指华为）外，O（指OPPO）也在推进阔直板量产机型，不过产品暂未最终定版。    

    至于其它手机厂商，大多仍停留在评估阶段，暂时没有明确的量产规划，后续是否跟进，很大程度上要看首款产品的市场反响。    对于阔直板手机的尺寸选择，有网友希望厂商推出7英寸以上机型。    

    对此，该博主表示，目前华为和OPPO都聚焦在6.3-6.4英寸左右，主要还是考虑便携性，“7英寸阔比例单手握持有点困难，我摸过，除非定义为游戏机。”     

    此外，还有网友询问玄戒芯片后续是否会用于直板手机，该博主回应称，暂时没有计划。    据了解，华为Pura X View业界首发16:9.5阔型屏幕，采用四等边窄边框设计，四边黑边宽度均为1.05mm，屏占比达到96.1%。     这块屏幕尺寸为6.39英寸，显示面积达到114.27cm²，实际显示内容量超过部分6.9英寸传统直板手机。    得益于更宽的屏幕比例，华为Pura X View在影音、阅读、游戏和办公等场景下，都能获得更大的横向显示空间。    例如横屏播放16:9比例影视剧、综艺和赛事视频时，画面两侧黑边更窄；刷竖屏短视频时，也能获得更大的显示面积。    机身方面，华为Pura X View重量约201g，厚度为6.68mm，在阔屏设计下仍兼顾了单手握持体验。    同时，新机还内置7000mAh大容量电池，在保持轻薄机身的同时进一步强化续航表现。    

华为Pura X View